Update on Bile Acid Malabsorption: Finally Ready for Prime Time?

Priya Vijayvargiya, Michael Camilleri

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose of Review: To provide an update on the prevalence, pathophysiology, disease associations, and treatment options for bile acid malabsorption (BAM). Recent Findings: •Molecular mechanisms—BAs prevent water reabsorption and increase water secretion by intracellular mediators, increasing aquaporin channels and intracellular permeability. •Inflammatory bowel disease—new molecular mechanisms of BAM are identified in patients without ileal disease, including changes in expression of ileal BA transporter and nuclear receptors involved in BA homeostasis. •Microscopic colitis—BAM is one of the mechanisms leading to microscopic colitis. •Diagnostic testing—new diagnostic tests have been launched in the USA (serum C4 and fecal 48-h BA excretion); stimulated FGF19 has higher detection of BAM compared to fasting sample alone. •Treatment—investigational FXR agonists may provide a daily, oral option for treatment of BAM instead of BA sequestrants. Summary: There is a greater appreciation of the biological role of bile acids across multiple fields of medicine, including gastrointestinal indications.

Original languageEnglish (US)
Article number10
JournalCurrent Gastroenterology Reports
Volume20
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Bile Acids and Salts
Microscopic Colitis
Ileal Diseases
Aquaporins
Water
Cytoplasmic and Nuclear Receptors
Routine Diagnostic Tests
Permeability
Fasting
Homeostasis
Medicine
Therapeutics
Serum

Keywords

  • Bile acid malabsorption
  • Colonic mechanisms
  • Fibroblast growth factor
  • FXR agonists
  • Inflammatory bowel disease
  • Microscopic colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Update on Bile Acid Malabsorption : Finally Ready for Prime Time? / Vijayvargiya, Priya; Camilleri, Michael.

In: Current Gastroenterology Reports, Vol. 20, No. 3, 10, 01.03.2018.

Research output: Contribution to journalArticle

@article{e7009eb9d851424fbea303713d3a2b1d,
title = "Update on Bile Acid Malabsorption: Finally Ready for Prime Time?",
abstract = "Purpose of Review: To provide an update on the prevalence, pathophysiology, disease associations, and treatment options for bile acid malabsorption (BAM). Recent Findings: •Molecular mechanisms—BAs prevent water reabsorption and increase water secretion by intracellular mediators, increasing aquaporin channels and intracellular permeability. •Inflammatory bowel disease—new molecular mechanisms of BAM are identified in patients without ileal disease, including changes in expression of ileal BA transporter and nuclear receptors involved in BA homeostasis. •Microscopic colitis—BAM is one of the mechanisms leading to microscopic colitis. •Diagnostic testing—new diagnostic tests have been launched in the USA (serum C4 and fecal 48-h BA excretion); stimulated FGF19 has higher detection of BAM compared to fasting sample alone. •Treatment—investigational FXR agonists may provide a daily, oral option for treatment of BAM instead of BA sequestrants. Summary: There is a greater appreciation of the biological role of bile acids across multiple fields of medicine, including gastrointestinal indications.",
keywords = "Bile acid malabsorption, Colonic mechanisms, Fibroblast growth factor, FXR agonists, Inflammatory bowel disease, Microscopic colitis",
author = "Priya Vijayvargiya and Michael Camilleri",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s11894-018-0615-z",
language = "English (US)",
volume = "20",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Update on Bile Acid Malabsorption

T2 - Finally Ready for Prime Time?

AU - Vijayvargiya, Priya

AU - Camilleri, Michael

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose of Review: To provide an update on the prevalence, pathophysiology, disease associations, and treatment options for bile acid malabsorption (BAM). Recent Findings: •Molecular mechanisms—BAs prevent water reabsorption and increase water secretion by intracellular mediators, increasing aquaporin channels and intracellular permeability. •Inflammatory bowel disease—new molecular mechanisms of BAM are identified in patients without ileal disease, including changes in expression of ileal BA transporter and nuclear receptors involved in BA homeostasis. •Microscopic colitis—BAM is one of the mechanisms leading to microscopic colitis. •Diagnostic testing—new diagnostic tests have been launched in the USA (serum C4 and fecal 48-h BA excretion); stimulated FGF19 has higher detection of BAM compared to fasting sample alone. •Treatment—investigational FXR agonists may provide a daily, oral option for treatment of BAM instead of BA sequestrants. Summary: There is a greater appreciation of the biological role of bile acids across multiple fields of medicine, including gastrointestinal indications.

AB - Purpose of Review: To provide an update on the prevalence, pathophysiology, disease associations, and treatment options for bile acid malabsorption (BAM). Recent Findings: •Molecular mechanisms—BAs prevent water reabsorption and increase water secretion by intracellular mediators, increasing aquaporin channels and intracellular permeability. •Inflammatory bowel disease—new molecular mechanisms of BAM are identified in patients without ileal disease, including changes in expression of ileal BA transporter and nuclear receptors involved in BA homeostasis. •Microscopic colitis—BAM is one of the mechanisms leading to microscopic colitis. •Diagnostic testing—new diagnostic tests have been launched in the USA (serum C4 and fecal 48-h BA excretion); stimulated FGF19 has higher detection of BAM compared to fasting sample alone. •Treatment—investigational FXR agonists may provide a daily, oral option for treatment of BAM instead of BA sequestrants. Summary: There is a greater appreciation of the biological role of bile acids across multiple fields of medicine, including gastrointestinal indications.

KW - Bile acid malabsorption

KW - Colonic mechanisms

KW - Fibroblast growth factor

KW - FXR agonists

KW - Inflammatory bowel disease

KW - Microscopic colitis

UR - http://www.scopus.com/inward/record.url?scp=85044533576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044533576&partnerID=8YFLogxK

U2 - 10.1007/s11894-018-0615-z

DO - 10.1007/s11894-018-0615-z

M3 - Article

C2 - 29582208

AN - SCOPUS:85044533576

VL - 20

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 3

M1 - 10

ER -